Canopy Growth (WEED) Aperçu de l'action
Canopy Growth Corporation et ses filiales produisent, distribuent et vendent des produits à base de cannabis et de chanvre à des fins récréatives et médicales, principalement aux États-Unis, au Canada, en Allemagne et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 1/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
WEED Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Canopy Growth Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CA$1.46 |
| Plus haut sur 52 semaines | CA$3.28 |
| Plus bas sur 52 semaines | CA$1.18 |
| Bêta | 2.39 |
| Variation sur 1 mois | -22.75% |
| Variation sur 3 mois | -10.98% |
| Variation sur 1 an | -41.83% |
| Variation sur 3 ans | -87.83% |
| Variation sur 5 ans | -99.54% |
| Évolution depuis l'introduction en bourse | -94.36% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).
Mise à jour du récit • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).Mise à jour du récit • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.Recent updates
Mise à jour du récit • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).Mise à jour du récit • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).Mise à jour du récit • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.Mise à jour du récit • Mar 28
WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).Mise à jour du récit • Mar 13
WEED: Term Loan And Equity Raise Will Support Future Acquisitions
Analysts have trimmed their CA$ price target on Canopy Growth, citing slightly higher projected revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple. Together, these factors imply a more cautious stance on the shares.Mise à jour du récit • Feb 26
WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion
Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).Mise à jour du récit • Feb 11
WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Analysts have trimmed their fair value estimate for Canopy Growth from $8.00 to $5.00, citing higher assumed revenue growth of 14.73% paired with much thinner profit margins of 4.78% and a very large 137.82x future P/E, which together point to a riskier and more expensive earnings profile. What's in the News Canopy Growth entered a term loan agreement to receive net proceeds of US$150 million from lenders led by JGB Management Inc., with the loan maturing in January 2031.Mise à jour du récit • Jan 27
WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from US$3.76 to about US$3.20. This reflects updated assumptions around slower revenue growth, a slightly lower future P/E, and a broadly unchanged margin and discount rate profile.Article d’analyse • Jan 11
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 28%
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 28% after a relatively good period...Mise à jour du récit • Jan 11
WEED: Medical And Adult Use Product Expansion Will Drive Future Upside
Analysts have made only very small tweaks to their inputs for Canopy Growth, keeping the fair value estimate steady at $3.76 while slightly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these changes support a largely unchanged price target outlook.Mise à jour du récit • Dec 23
WEED: Medical Expansion Will Drive Future Upside For Shares
Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.Mise à jour du récit • Dec 08
WEED: Medical Expansion And Share Consolidation Will Drive Future Upside
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples. What's in the News Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments) Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments) Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments) Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments) Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments) Valuation Changes Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.Mise à jour du récit • Nov 24
WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside
Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.Article d’analyse • Nov 15
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 26% after a relatively good period...Article d’analyse • Nov 10
Canopy Growth Corporation (TSE:WEED) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Canopy Growth Corporation ( TSE:WEED ) released its second-quarter result to the...Mise à jour du récit • Nov 10
WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead
Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.Article d’analyse • Aug 30
Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
Canopy Growth Corporation ( TSE:WEED ) shares have had a really impressive month, gaining 70% after a shaky period...Mise à jour du récit • Aug 07
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.Article d’analyse • May 18
Investors Appear Satisfied With Canopy Growth Corporation's (TSE:WEED) Prospects As Shares Rocket 40%
Those holding Canopy Growth Corporation ( TSE:WEED ) shares would be relieved that the share price has rebounded 40% in...Article d’analyse • Apr 02
What You Can Learn From Canopy Growth Corporation's (TSE:WEED) P/S After Its 28% Share Price Crash
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 28% in the last...
Nouveau récit • Mar 31
New Medical Cannabis And Vaporizer Offerings Will Expand Global Markets
Growth in the medical cannabis sector and product innovation in adult-use and premium vaporizers position Canopy for revenue and market share expansion.Article d’analyse • Feb 12
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...Article d’analyse • Dec 22
Canopy Growth Corporation's (TSE:WEED) Popularity With Investors Under Threat As Stock Sinks 26%
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...Article d’analyse • Nov 05
Canopy Growth Corporation (TSE:WEED) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Canopy Growth Corporation ( TSE:WEED ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Article d’analyse • Aug 28
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 26%
To the annoyance of some shareholders, Canopy Growth Corporation ( TSE:WEED ) shares are down a considerable 26% in the...Article d’analyse • Aug 17
We Think Canopy Growth (TSE:WEED) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jun 15
Some Confidence Is Lacking In Canopy Growth Corporation (TSE:WEED) As Shares Slide 26%
Canopy Growth Corporation ( TSE:WEED ) shares have retraced a considerable 26% in the last month, reversing a fair...Rendement pour les actionnaires
| WEED | CA Pharmaceuticals | CA Marché | |
|---|---|---|---|
| 7D | 2.8% | 1.3% | 1.5% |
| 1Y | -41.8% | 45.3% | 33.7% |
Rendement vs Industrie: WEED a sous-performé le secteur Canadian Pharmaceuticals qui a rapporté 45.3 % au cours de l'année écoulée.
Rendement vs marché: WEED a sous-performé le marché Canadian qui a rapporté 33.7 % au cours de l'année écoulée.
Volatilité des prix
| WEED volatility | |
|---|---|
| WEED Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 18.0% |
| 10% least volatile stocks in CA Market | 3.9% |
Cours de l'action stable: WEED n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Canadian.
Volatilité au fil du temps: La volatilité hebdomadaire de WEED ( 10% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 960 | Luc Mongeau | www.canopygrowth.com |
Canopy Growth Corporation, avec ses filiales, se consacre à la production, à la distribution et à la vente de produits à base de cannabis et de chanvre à des fins récréatives et médicales, principalement aux États-Unis, au Canada, en Allemagne et dans le monde entier. Elle exerce ses activités par l'intermédiaire des segments Canada Cannabis, International Markets Cannabis et Storz & Bickel. L'entreprise propose des fleurs séchées, des joints pré-roulés, des huiles, des capsules molles, des boissons infusées, des edibles comprenant des gommes et des formats topiques, ainsi que des dispositifs de vaporisation.
Canopy Growth Corporation Résumé des fondamentaux
| WEED statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CA$567.42m |
| Bénéfices(TTM) | -CA$327.29m |
| Recettes(TTM) | CA$278.39m |
2.0x
Ratio P/S-1.7x
Ratio P/ELe site WEED est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| WEED compte de résultat (TTM) | |
|---|---|
| Recettes | CA$278.39m |
| Coût des recettes | CA$204.45m |
| Marge brute | CA$73.94m |
| Autres dépenses | CA$401.24m |
| Les revenus | -CA$327.29m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
Jun 15, 2026
| Résultat par action (EPS) | -0.86 |
| Marge brute | 26.56% |
| Marge bénéficiaire nette | -117.57% |
| Ratio dettes/capitaux propres | 29.7% |
Quelles ont été les performances à long terme de WEED?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 11:58 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Canopy Growth Corporation est couverte par 23 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |